Alzheimer’s disease

Quick Take: Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

Alzheimer disease (AD) is characterized by the accumulation of amyloid b (Ab) and tau aggregates in the brain. The progression of AD can be monitored through imaging techniques or through the use of cerebrospinal fluid (CSF) biomarkers. As these modalities are expensive and invasive, an alternative method is needed. Neurofilament Czytaj więcej…

Alzheimer’s disease

Verubecestat linked to worse outcomes among patients with prodromal Alzheimer’s Disease compared to placebo

1. Verubecestat, an orally administered beta amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor , did not slow or prevent the progression of dementia among patients with prodromal Alzheimer’s disease. 2. Adverse events were more often noted in the verubecestat groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prodromal Czytaj więcej…